New research has uncovered immune changes in cancer patients that could help identify which patients are most at risk of dangerous heart complications from cancer drugs, known as immune checkpoint ...

Cancer immunotherapy has historically focused on harnessing the ability of T cells to recognize and attack cancer cells. Adaptive immune checkpoint inhibitors (ICIs) unleash tumor-infiltrating ...

This Research Topic is one volume within the series "The Future of Checkpoint Immunotherapy: New Roads Ahead". Please see the ...

Please provide your email address to receive an email when new articles are posted on . Glucocorticoids remain the primary option for immune-related adverse events of checkpoint inhibitor therapy in ...

Feasibility Study for Using Large Language Models to Identify Goals-of-Care Documentation at Scale in Patients With Advanced Cancer A retrospective analysis of 3,626 patients treated with ICIs for ...

Inhibrx Biosciences, Inc. INBX shares are trading higher on Monday as the company is reporting positive interim results from ...

ICIs combined with chemotherapy showed higher efficacy than bevacizumab in treating advanced driver gene–negative NS-NSCLC. The study reported improved PFS and OS for patients receiving ICIs compared ...

A recent study found that monthly prices of checkpoint inhibitors decreased only slightly from 2015 to 2024, with declines in annual average sales prices ranging from 0.21% to 4.85%. "Prices of ...

Ernexa Therapeutics reported new preclinical findings showing its ERNA-101 cell therapy candidate achieved complete tumor ...

Please provide your email address to receive an email when new articles are posted on . More than 50% of adenomas developed within 7.5 months of immune checkpoint inhibitor-mediated diarrhea and ...